Unbridged bis-aryl carbinol derivatives, compositions and methods of use
    2.
    发明授权
    Unbridged bis-aryl carbinol derivatives, compositions and methods of use 失效
    未桥连的双芳基甲醇衍生物,组合物和使用方法

    公开(公告)号:US5679692A

    公开(公告)日:1997-10-21

    申请号:US307801

    申请日:1994-09-26

    摘要: Disclosed is a compound of Formula 1.0: ##STR1## or a pharmaceutically acceptable salt or solvate thereof, wherein: AR.sup.1 represents ##STR2## AR.sup.2 represents ##STR3## or a five-membered heterocyclic aromatic group selected from the group consisting of Formulas I to XII, wherein the substitutable carbon atoms of the five-membered heterocyclic group can optionally be substituted with a group R.sup.1. Also disclosed are pharmaceutical compositions containing compounds of Formula 1.0. Further disclosed is a method for treating asthma, allergy and inflammation by administering an anti-asthmatic, anti-allergic or anti-inflammatory, respectively, effective amount of a compound of Formula 1.0.

    摘要翻译: PCT No.PCT / US93 / 02289 Sec。 371日期:1994年9月26日 102(e)1994年9月26日PCT 1993年3月22日PCT公布。 WO93 / 20063 PCT出版物 日期:1993年10月14日公开是式1.0的化合物:其中:AR1表示“IMA”或“5”元杂环芳基,其选自 由式I至XII组成的组,其中五元杂环基的可取代的碳原子可以任选地被基团R 1取代。 还公开了含有式1.0化合物的药物组合物。 还公开了一种通过分别施用抗哮喘,抗过敏或抗炎的有效量的式1.0化合物来治疗哮喘,过敏和炎症的方法。

    Unbridged bis-aryl carbinol derivatives compositions and methods of use
    4.
    发明授权
    Unbridged bis-aryl carbinol derivatives compositions and methods of use 失效
    未桥连的双芳基甲醇衍生物组合物和使用方法

    公开(公告)号:US5665735A

    公开(公告)日:1997-09-09

    申请号:US459149

    申请日:1995-06-02

    摘要: Disclosed is a compound of Formula 1.0: ##STR1## or a pharmaceutically acceptable salt or solvate thereof, wherein: AR.sup.1 represents ##STR2## AR.sup.2 represents ##STR3## or a five-membered heterocyclic aromatic group selected from the group consisting of Formulas I to XII, wherein the substitutable carbon atoms of the five-membered heterocyclic group can optionally be substituted with a group R.sup.1.Also disclosed are pharmaceutical compositions containing compounds of Formula 1.0.Further disclosed is a method for treating asthma, allergy and inflammation by administering an anti-asthmatic, anti-allergic or anti-inflammatory, respectively, effective amount of a compound of Formula 1.0.

    摘要翻译: 公开了式1.0的化合物:其中:AR1表示SEQ ID NO:表示选自下式的五元杂环芳族基团:式(1.0)或其药学上可接受的盐或溶剂合物, I至XII,其中五元杂环基的可取代的碳原子可任选地被基团R 1取代。 还公开了含有式1.0化合物的药物组合物。 还公开了一种通过分别施用抗哮喘,抗过敏或抗炎的有效量的式1.0化合物来治疗哮喘,过敏和炎症的方法。

    Imidazo- and pyrimido-quinoline, naphthyridine and pyridopyrazine
compounds
    5.
    发明授权
    Imidazo- and pyrimido-quinoline, naphthyridine and pyridopyrazine compounds 失效
    咪唑并 - 嘧啶 - 喹啉,萘啶和吡啶并吡嗪化合物

    公开(公告)号:US5070086A

    公开(公告)日:1991-12-03

    申请号:US499473

    申请日:1990-06-15

    申请人: Richard Friary

    发明人: Richard Friary

    IPC分类号: C07D471/04 C07D471/14

    CPC分类号: C07D471/04 C07D471/14

    摘要: Imidazo- and pyrimido-quinoline, naphthyridine and pyridopyrazine compounds, methods of making said compounds and their use as anti-allergy, antiinflammatory and/or agents for the treatment of hyperproliferative skin disease are disclosed.

    摘要翻译: 公开了咪唑并 - 嘧啶 - 喹啉,萘啶和吡啶并吡嗪化合物,制备所述化合物的方法及其用作抗过敏,抗炎和/或治疗过度增生性皮肤病的药剂。